Market Place
Sourcing Support
UNION Announces ADESOS Phase 2b Results For Orismilast
25 Sep 2024 //
PR NEWSWIRE
UNION to present orismilast Phase 2b results in atopic dermatitis
20 Sep 2024 //
PR NEWSWIRE
UNION: ADESOS Phase 2b Success, Data At RAVE Conference 2024
04 Jun 2024 //
PR NEWSWIRE
UNION therapeutics to present at 7th Annual Dermatology Drug Development Summit
25 Oct 2023 //
PR NEWSWIRE
UNION therapeutics announces presentation of new data on orismilast
06 Oct 2023 //
PR NEWSWIRE
Altis Labs reels in $6M in seed funding for AI imaging
21 Jun 2023 //
FIERCE BIOTECH
UNION therapeutics to participate at Kempen Life Science Conference
21 Apr 2023 //
PR NEWSWIRE
US FDA grants Fast Track status for UNION’s oral orismilast to treat HS
11 Jan 2023 //
PHARMACEUTICAL-TECHNOLOGY
UNION announces positive results from IASOS Phase 2b study of oral orismilast
09 Jan 2023 //
PR NEWSWIRE
First large-scale analysis confirms that vulnerable patients increased fatality
02 Jan 2023 //
CISION
Innovent & UNION Announce First Subject Dosed in a Chinese PhI Study Orismilast
04 Dec 2022 //
PRNEWSWIRE
UNION presents new data on orismilast at the 31st EADV Congress
09 Sep 2022 //
PRESS RELEASE
UNION announces regulatory approval of Treatment for ongoing OSIRIS Ph2a
01 Sep 2022 //
CISION
Union begins enrolment in Phase IIb atopic dermatitis trial
05 Aug 2022 //
CLINICALTRIALSARENA
UNION Tx Begins enrollment in ADESOS PIIb study of orismilast MR tablet
04 Aug 2022 //
PRNEWSWIRE
UNION therapeutics begis enrollment in IASOS Phase 2b study of oral orismilast
04 Jan 2022 //
PRNEWSWIRE
FDA fast track oral treatment of dermatitis
04 Nov 2021 //
PHARMAFILE
UNION therapeutics announces enrollment of first patient in the PREVENT study
22 Oct 2021 //
CISION
UNION announces enrollment of first patient in the OSIRIS Phase 2a study
14 Oct 2021 //
PRNEWSWIRE
UNION therapeutics’ Covid-19 candidates meet endpoints in trial
07 Apr 2021 //
CLINICALTRIALSARENA
UNION ` COVID-19 candidates found to be well tolerated in Phase 1
06 Apr 2021 //
PRNEWSWIRE
UNION receives FDA approval for IND of oral next generation PDE4-inhibitor
07 Jan 2021 //
PRNEWSWIRE
UNION receives FDA approval for IND of oral next generation PDE4
07 Jan 2021 //
PRNEWSWIRE
UNION therapeutics A/S completes dosing of healthy volunteers with UNI911
24 Aug 2020 //
PRNEWSWIRE
TFF Pharmaceuticals Signs Worldwide Licensing Agreement with Union Therapeutics
17 Aug 2020 //
CONTRACTPHARMA
UNION therapeutics announces acquisition of PDE4i compound class from LEO
21 Jul 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.